Invectys Receives its Second MATWIN Award
Invectys awarded “2023 Best Translational Development” by the MATWIN international Board Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…
Read more
Invectys awarded “2023 Best Translational Development” by the MATWIN international Board Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…
Invectys is part of project “Melomanes”! Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma,…
INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
The main product of Invectys is a DNA vaccine targeting Telomerase…